...
首页> 外文期刊>Advances in immunology >The Intestinal Microbiota in Chronic Liver Disease
【24h】

The Intestinal Microbiota in Chronic Liver Disease

机译:慢性肝病中的肠道菌群

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Recent evidence indicates that the intestinal microflora plays a critical role in physiological and pathological processes; in particular, it is now considered a key determinant of immune pathologies and metabolic syndrome. Receiving the majority of its blood supply from the portal vein, the liver represents the first line of defense against food antigens, toxins, microbial-derived products, and microorganisms. Moreover, the liver is critically positioned to integrate metabolic outcomes with nutrient intake. To accomplish this function, the liver is equipped with a broad array of immune networks. It is now evident that, during pathological processes associated with obesity, alcohol-intake, or autoimmunity, the interaction between these immune cell populations and the intestinal microbiota promotes chronic liver disease progression and therefore they represent a novel therapeutic target. Herein, we highlight recent studies that have shed new light on the relationship between the microbiome, the innate immune system, and chronic liver disease progression.
机译:最近的证据表明,肠道菌群在生理和病理过程中起着至关重要的作用。特别是现在,它被认为是免疫病理和代谢综合征的关键决定因素。肝脏从门静脉获得大部分血液供应,是抵御食物抗原,毒素,微生物衍生产品和微生物的第一道防线。此外,肝脏处于至关重要的位置,可以将代谢结果与营养摄入结合起来。为了实现这一功能,肝脏配备了各种各样的免疫网络。现在很明显,在与肥胖,饮酒或自身免疫有关的病理过程中,这些免疫细胞群与肠道菌群之间的相互作用促进了慢性肝病的进展,因此它们代表了一种新型的治疗靶点。在本文中,我们重点介绍了最近的研究,这些研究为微生物组,先天免疫系统与慢性肝病进展之间的关系提供了新的启示。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号